Skip to main content
Figure 3 | Cardiovascular Diabetology

Figure 3

From: Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner

Figure 3

Ex vivo myocardial infarct size expressed as a percentage of the risk zone. The reduction in myocardial infarct to area at risk ratio (I/R%) induced by pre-treatment with Vildagliptin (Vilda) was abolished by treatment with either Exendin 9–39 (Exendin), a GLP-1 receptor antagonist, or H-89 (a PKA antagonist). *P < 0.05. N ≥ 6/group.

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840